Literature DB >> 28545937

Treatment of NAFLD with diet, physical activity and exercise.

Manuel Romero-Gómez1, Shira Zelber-Sagi2, Michael Trenell3.   

Abstract

Lifestyle intervention can be effective when treating non-alcoholic fatty liver diseases (NAFLD) patients. Weight loss decreases cardiovascular and diabetes risk and can also regress liver disease. Weight reductions of ⩾10% can induce a near universal non-alcoholic steatohepatitis resolution and fibrosis improvement by at least one stage. However, modest weight loss (>5%) can also produce important benefits on the components of the NAFLD activity score (NAS). Additionally, we need to explore the role of total calories and type of weight loss diet, micro- and macronutrients, evidence-based benefits of physical activity and exercise and finally support these modifications through established behavioural change models and techniques for long-term maintenance of lifestyle modifications. Following a Mediterranean diet can reduce liver fat even without weight loss and is the most recommended dietary pattern for NAFLD. The Mediterranean diet is characterised by reduced carbohydrate intake, especially sugars and refined carbohydrates (40% of the calories vs. 50-60% in a typical low fat diet), and increased monounsaturated and omega-3 fatty acid intake (40% of the calories as fat vs. up-to 30% in a typical low fat diet). Both TV sitting (a reliable marker of overall sedentary behaviour) and physical activity are associated with cardio-metabolic health, NAFLD and overall mortality. A 'triple hit behavioural phenotype' of: i) sedentary behaviour, ii) low physical activity, and iii) poor diet have been defined. Clinical evidence strongly supports the role of lifestyle modification as a primary therapy for the management of NAFLD and NASH. This should be accompanied by the implementation of strategies to avoid relapse and weight regain.
Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Behaviour intervention; Exercise; Fibrosis; Mediterranean diet; Physical activity; Steatohepatitis; Steatosis; Weight loss

Mesh:

Substances:

Year:  2017        PMID: 28545937     DOI: 10.1016/j.jhep.2017.05.016

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  270 in total

1.  S-allylmercaptocysteine improves nonalcoholic steatohepatitis by enhancing AHR/NRF2-mediated drug metabolising enzymes and reducing NF-κB/IκBα and NLRP3/6-mediated inflammation.

Authors:  Qian Yu; Yann-Yin Lee; Zheng-Yun Xia; Emily C Liong; Jia Xiao; George L Tipoe
Journal:  Eur J Nutr       Date:  2020-06-17       Impact factor: 5.614

2.  Long-term exercise prevents hepatic steatosis: a novel role of FABP1 in regulation of autophagy-lysosomal machinery.

Authors:  Huifeng Pi; Mengyu Liu; Yu Xi; Mengyan Chen; Li Tian; Jia Xie; Mingliang Chen; Zhen Wang; Min Yang; Zhengping Yu; Zhou Zhou; Feng Gao
Journal:  FASEB J       Date:  2019-07-31       Impact factor: 5.191

3.  Pyroptosis: An inflammatory link between NAFLD and NASH with potential therapeutic implications.

Authors:  Juliane I Beier; Jesus M Banales
Journal:  J Hepatol       Date:  2018-02-14       Impact factor: 25.083

Review 4.  Exercising the hepatobiliary-gut axis. The impact of physical activity performance.

Authors:  Emilio Molina-Molina; Raquel Lunardi Baccetto; David Q-H Wang; Ornella de Bari; Marcin Krawczyk; Piero Portincasa
Journal:  Eur J Clin Invest       Date:  2018-06-14       Impact factor: 4.686

Review 5.  Current management of non-alcoholic steatohepatitis.

Authors:  Mark D Muthiah; Arun J Sanyal
Journal:  Liver Int       Date:  2020-02       Impact factor: 5.828

Review 6.  Efficacy and Safety of Intragastric Balloon (IGB) in Non-alcoholic Fatty Liver Disease (NAFLD): a Comprehensive Review and Meta-analysis.

Authors:  Saurabh Chandan; Babu P Mohan; Shahab R Khan; Antonio Facciorusso; Daryl Ramai; Lena L Kassab; Neil Bhogal; Ravishankar Asokkumar; Gortrand Lopez-Nava; Stephanie McDonough; Douglas G Adler
Journal:  Obes Surg       Date:  2021-01-06       Impact factor: 4.129

Review 7.  Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment.

Authors:  Ming-Ming Chen; Jing-Jing Cai; Yao Yu; Zhi-Gang She; Hongliang Li
Journal:  Gene Expr       Date:  2019-04-02

8.  Persistent changes in liver methylation and microbiome composition following reversal of diet-induced non-alcoholic-fatty liver disease.

Authors:  Hyejin Kim; Oliver Worsley; Edwin Yang; Rikky Wenang Purbojati; Ai Leng Liang; Wilson Tan; Daniela I Drautz Moses; Septian Hartono; Vanessa Fan; Tony Kiat Hon Lim; Stephan C Schuster; Roger Sy Foo; Pierce Kah Hoe Chow; Sven Pettersson
Journal:  Cell Mol Life Sci       Date:  2019-05-22       Impact factor: 9.261

Review 9.  Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State?

Authors:  Margaret Spinosa; Jonathan G Stine
Journal:  Curr Pharm Des       Date:  2020       Impact factor: 3.116

10.  Free-breathing liver fat and R 2 quantification using motion-corrected averaging based on a nonlocal means algorithm.

Authors:  Huiwen Luo; Ante Zhu; Curtis N Wiens; Jitka Starekova; Ann Shimakawa; Scott B Reeder; Kevin M Johnson; Diego Hernando
Journal:  Magn Reson Med       Date:  2020-08-01       Impact factor: 4.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.